TXA in TARNCT07828262
The Use of Tranexamic Acid in Decreasing Wound Complication in Total Ankle Replacement.
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Secondary endpoints revised (8)
- Study title shortened, about 5 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Patients will receive 1.5g of TXA in 100ml normal saline (NS) solution intravenously within our hour prior to skin incision, and prior to tourniquet inflation. A second dose of 3g in 100ml NS of tranexamic acid will be given topically through a soaked sponge after implant placement and prior to closure. This will be left in place for five minutes.
Patients will receive either 100ml normal saline (NS) solution intravenously within our hour prior to skin incision, and prior to tourniquet inflation. Then, a 100ml normal saline solution will be given topically through a soaked sponge after implant placement and prior to closure. This will be left in place for five minutes.
Drugs: Transexamic acid, Normal Saline (0.9% NaCl)
Sites
1 site in 1 country
- The Ottawa Hospital Civic CampusOttawa, Ontario, Canada